Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, single-arm phase II clinical trial investigating the
efficacy and safety of niraparib monotherapy maintenance in HRD-positive newly diagnosed
advanced epithelial ovarian cancer (EOC), including primary peritoneal and/or fallopian tube
tumors, following response to front-line chemotherapy in combination with bevacizumab. A
total of 116 patients will be enrolled.